LATE-BREAKING ABSTRACT: Morbidity and mortality of chronic heart failure (CHF) patients with central sleep apnoea (CSA) treated by adaptive servoventilation (ASV): Interim results of FACE cohort study

Abstract

Introduction: CSA is associated with a worse prognosis of CHF. The national multicentre cohort study FACE is collecting real-world clinical data of CHF patients with CSA eligible for ASV therapy in addition to selected population of SERVE-HF trial. Aims and Methods: Morbidity and mortality, cardiac function and quality of life are assessed over a period of 2 years depending on whether the patient was compliant (≥3h/night) with ASV therapy (ResMed, AutoSet CS) or not (control). Interim 1-2 year follow-up (FU) data are presented here. Results: 361 CHF pts with CSA were included in the ITT analysis. Median FU for analysis was 11 months. Baseline characteristics were: age 70.7±11.0 y, 88% male, body mass index 28.1±5.1 kg/m 2 . Left ventricular ejection fraction (LVEF) was reduced or preserved in 65% (CHF-REF) and 35% (CHF-PEF) of patients, respectively. 71% had predominantly CSA, and 29% had coexisting CSA and obstructive apnoea (CSA-OSA). 66% of patients were compliant to ASV therapy. Globally, adjusted multivariate analysis did not confirm any benefit or deleterious effect of ASV. However, CHF-REF with predominant CSA and CHF-REF patients with implanted cardiac defibrillator seemed to have poorer prognosis under ASV therapy compared to untreated patients. Conversely, other CHF populations (CHF-PEF or CSA-OSA) treated with ASV may have better survival. Conclusion: These results are consistent with those of SERVE-HF trial. Furthermore, the FACE cohort study may be a useful tool to better understand the impact of ASV therapy in other CHF populations with CSA, especially in CHF-PEF or CHF with CSA-OSA.